<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[SBGrid Community News - Medium]]></title>
        <description><![CDATA[News and highlights about scientists and software developers in the SBGrid community. The SBGrid Communities Project demonstrates how structural biology and preclinical science connect to medicine, a collaboration between SBGrid PI Piotr Sliz Jamaine Davis of Belmont University - Medium]]></description>
        <link>https://medium.com/sbgrid-community-news?source=rss----4f09a70358f6---4</link>
        <image>
            <url>https://cdn-images-1.medium.com/proxy/1*TGH72Nnw24QL3iV9IOm4VA.png</url>
            <title>SBGrid Community News - Medium</title>
            <link>https://medium.com/sbgrid-community-news?source=rss----4f09a70358f6---4</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 12:00:40 GMT</lastBuildDate>
        <atom:link href="https://medium.com/feed/sbgrid-community-news" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Teaching AI to spot new tuberculosis drugs]]></title>
            <link>https://medium.com/sbgrid-community-news/teaching-ai-to-spot-new-tuberculosis-drugs-bc7e4e5dc40f?source=rss----4f09a70358f6---4</link>
            <guid isPermaLink="false">https://medium.com/p/bc7e4e5dc40f</guid>
            <category><![CDATA[artificial-intelligence]]></category>
            <category><![CDATA[antibiotics]]></category>
            <category><![CDATA[structural-biology]]></category>
            <category><![CDATA[sbgrid]]></category>
            <category><![CDATA[tuberculosis]]></category>
            <dc:creator><![CDATA[SBGrid]]></dc:creator>
            <pubDate>Wed, 28 Oct 2026 20:54:20 GMT</pubDate>
            <atom:updated>2026-10-28T21:19:21.788Z</atom:updated>
            <content:encoded><![CDATA[<h4>Publication Highlight</h4><p><em>This publication highlight is part of the SBGrid Communities Project focused on science education and demonstrating how structural biology and preclinical science connect to medicine, a collaboration between SBGrid PI Piotr Sliz and Jamaine Davis of Belmont University.</em></p><p>The development of new antibiotics has declined, but the incidence of drug-resistant Tuberculosis (TB) has remained around 390,000 and continues to pose significant public health challenges. TB is currently the world’s leading cause of death from a single infectious agent with approximately 1.23 million deaths per year. TB is one of the <a href="https://www.who.int/news-room/fact-sheets/detail/tuberculosis">top 10 causes of death worldwide</a> and in low-income countries it is ranked above road injuries in <a href="https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death">2023</a>. Its death toll is made worse because the bacterium <em>Mycobacterium tuberculosis (</em>Mtb<em>)</em> is increasingly resistant to the first line of antibiotics doctors rely on most, such as rifampicin. As a result, the World Health Organization (WHO) has added rifamicin-resistant TB to its Bacterial Priority Pathogens List, signaling an urgent need for new TB antibiotics.</p><p>Over the past few decades, scientists have found chemicals that stop TB from growing. The hard part is figuring out how they work, and is called its mechanism of action (MOA). Without this knowledge, scientists cannot tell which chemicals attack TB in new ways and which work in ways TB can already resist. This obstacle makes it harder to choose which chemicals to develop into drugs and slows progress toward better treatments for millions of people.</p><figure><img alt="Researcher holding a a scientific plate to examine bacteria growth." src="https://cdn-images-1.medium.com/max/962/1*TK0Ui0EJmOvWovWS9W4WaQ.png" /><figcaption>A drug susceptibility test for <em>Mycobacterium tuberculosis</em>. Each section of the plate tests a different condition, and sparse growth shows where the bacteria struggled to grow. Tests like this reveal if a chemical works, but not how. Image courtesy of Unsplash: <a href="https://unsplash.com/photos/a-person-holding-a-round-object-in-their-hands-y--8fqaK1kY">https://unsplash.com/photos/a-person-holding-a-round-object-in-their-hands-y--8fqaK1kY</a></figcaption></figure><p>Artificial intelligence (AI) is joining the fight against TB. To help accelerate the process of finding new TB drugs, SBGrid member Anne Marie Wehenkel and colleagues at Institut Pasteur in France built an AI tool that can identify a drug’s mechanism from photographs of bacteria with drugs. They used antibiotics for which scientists already understood the MOA to train AI for the future identification of new drugs.</p><p>However, building a new drug for TB is more complex than for other bacteria. Mtb have high variability from cell-to-cell, meaning they look very different from one another even when no drug is added. Some are long, some short, some lopsided. The small changes that drugs cause can get lost in their natural differences. Mtb is also dangerous to work with and only divides once a day, so the team used <em>Corynebacterium glutamicum</em> (Cglu), a harmless relative of TB that divides once every hour. Cglu shares TB’s thick cell wall and core machinery, making it a reliable reference.</p><p>To develop the AI the team created a training set of data. They started with 18 antibiotics with known MOAs. These drugs would cause damage that could be visualized under a microscope. Eleven of these drugs were used for “training”, covering 5 different mechanisms of attacking the bacteria, such as breaking down the cell wall or blocking the DNA copying machinery. The team treated Cglu with each drug, and then used a dye that stained them so they could see the cell membrane and DNA under the microscope. This process allowed them to easily take thousands of photos that were then labeled with how the drug works. The AI studied these photos, so it could learn what each kind of damage looked like.</p><p>In the first test, the team showed the AI new photos of different cells treated with the same 11 drugs. These cells came from a separate batch the AI had never seen. When asked to identify each drug’s mechanism, it did so with 87% accuracy, showing the AI had learned what each type of damage looked like, rather than memorizing specific photos.</p><p>Next, the team tested the AI on the 7 antibiotics it had not seen during training. Two of these had no effect on Cglu, and the AI correctly identified those cells as untreated. Three shared the same mechanisms from training, and the AI sorted all 3 into the right group. The last 2, rifampicin and rifabutin, used antibiotic mechanisms unknown to the AI. The AI could not name what these drugs were doing, but it recognized them as different from anything it had previously learned and set them in a separate group.</p><p>In a traditional drug search with thousands of chemicals, scientists aim to find distinct group/s of drugs. Rifampicin was tested because scientists knew how it worked, but drugs placed in the distinct group could represent those attacking TB in new ways, which would offer new forms of treatment. This AI tool is not ready to find the next TB drug yet, but it shows promise in demonstrating that microscope images hold more information than scientists have previously understood. If this approach holds in real chemical screenings, it could help researchers spend their time on the chemicals that are most likely to beat drug-resistant TB.</p><p>Read more in <a href="https://www.science.org/doi/10.1126/sciadv.aeg6806"><strong><em>Science Advances</em></strong></a>.</p><p><em>By Vina Nguyen (</em><a href="https://medium.com/u/694b2aa9585c"><em>Vina Nguyen</em></a><em>), Lipscomb University</em></p><p><em>Vina Nguyen is an undergraduate student at Lipscomb University, pursuing a Bachelor’s degree in Molecular Biology and minors in Chemistry and Fashion Merchandising. Beyond the classroom, she enjoys trying new recipes, exercising, and exploring local coffee shops.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=bc7e4e5dc40f" width="1" height="1" alt=""><hr><p><a href="https://medium.com/sbgrid-community-news/teaching-ai-to-spot-new-tuberculosis-drugs-bc7e4e5dc40f">Teaching AI to spot new tuberculosis drugs</a> was originally published in <a href="https://medium.com/sbgrid-community-news">SBGrid Community News</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Recognizing the worker that helps package herpesvirus]]></title>
            <link>https://medium.com/sbgrid-community-news/recognizing-the-worker-that-helps-package-herpesvirus-378a90700288?source=rss----4f09a70358f6---4</link>
            <guid isPermaLink="false">https://medium.com/p/378a90700288</guid>
            <category><![CDATA[anti-viral-drugs]]></category>
            <category><![CDATA[structural-biology]]></category>
            <category><![CDATA[sbgrid]]></category>
            <category><![CDATA[chicken-pox]]></category>
            <category><![CDATA[herpes-viruses]]></category>
            <dc:creator><![CDATA[SBGrid]]></dc:creator>
            <pubDate>Mon, 26 Oct 2026 22:56:27 GMT</pubDate>
            <atom:updated>2026-10-28T21:20:40.362Z</atom:updated>
            <content:encoded><![CDATA[<h4>Publication Highlight</h4><p><em>This publication highlight is part of the SBGrid Communities Project focused on science education and demonstrating how structural biology and preclinical science connect to medicine, a collaboration between SBGrid PI Piotr Sliz and Jamaine Davis of Belmont University.</em></p><p>Chickenpox was once very common, but is now preventable via vaccines. Many people do not know that chickenpox is caused by a member of the herpesvirus family. Meaning almost everyone has been affected by this family of viruses in some shape or form. There are nine types of herpesviruses across three subfamilies, with some causing significant harm. Investigating how these viruses divide and infect human cells has been helpful in maintaining the quality of life for individuals infected. Many proteins come together, similar to workers on an assembly line, to put pieces of the viral DNA into container-like structures called capsids. One protein of unknown function known to assist in this process is the packaging accessory factor. Though the mechanisms that allow this ‘worker’ to distribute viral DNA are unknown, it is known that without the worker, the viral DNA is not packaged nor distributed, stopping the infection of other cells. SBGrid Member Allison Didychuk and fellow researchers at Yale University used Cryo-EM to determine the structure of the accessory packaging factor from two herpesviruses, UL32 in HSV-1 and UL52 in HCMV, in hopes of determining its exact function.</p><figure><img alt="Image on left is a ribbon structure with box highlighting specific section. Image on right is colorful front view with each protein subunit in a different color." src="https://cdn-images-1.medium.com/max/1024/1*k7YBRyVMWoCcAS2qVe42Sw.png" /><figcaption>Left: Aligned ribbon view of UL52 (PDB 9ZM2) and UL32 (PDB 9ZLY), in light blue and light pink respectively, with positively charged residues lining inner channel, K563 and R572 on UL32, highlighted in yellow. The incomplete UL52 tetramer and pentameric UL32 are highlighted by the boxed pink ribbons in the upper-right region of the protein. (CC by SBGrid.) Right: Front view of tripentameric UL32 (PDB 9ZLY) with each protein subunit in different colors. (CC by SBGrid.)</figcaption></figure><p>While attempting to determine the structure of the UL32 and UL52, researchers compared it to the previously determined structure of the accessory packaging factor from KSHV, ORF68. They found that there were differences in the structure of the accessory packaging factor across subfamilies of herpesvirus, but that all form a 5-subunit ring with a generally shared structure. Within the center of this 5-subunit ring is an inner lining of positively charged amino acids proven essential in packaging viral DNA and contributing to the accessory packaging factor’s function. UL52, the accessory packing factor from HCMV, forms in an incomplete ring. Additionally researchers found that UL32, the accessory packaging factor from HSV-1, is capable of forming a larger protein complex through a combination of three of the 5-subunit rings. Its function is not yet determined, but this discovery points to the possibility that the accessory packaging factor functions as a larger complex assembly, rather than as the 5-subunit ring observed.</p><p>In the broader context, Herpesviruses are very complex, and sometimes can differ greatly even within the same subfamilies. While some antivirals are effective at managing viral division and infection of cells, some herpesviruses are non-responsive to antivirals. Only one vaccine is available for herpesvirus infections, the chickenpox vaccine, and this vaccine only prevents human herpesvirus 3 infections. Because Herpesviruses affect many people, this work is important to understanding how to combat these viruses and prevent disease. Using structural biology to understand how the accessory packaging factor aids in herpesvirus replication and infection, has the potential to provide avenues for drug discovery, antiviral design, and vaccine development.</p><p>Read more in <a href="https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1014540"><strong><em>PLOS Pathogens</em></strong></a>.</p><p><em>By Cariuna M. Ellison (</em><a href="https://medium.com/u/b8a86fe2142b"><em>Cariuna Ellison</em></a><em>), Fisk University</em></p><p><em>Cariuna M. Ellison is an undergraduate student at Fisk University, pursuing a Bachelor’s degree in Biochemistry and Molecular Biology. She is on track to graduate in May 2028. In her free time, she enjoys reading, exercising, and giving back to her community in any way she can.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=378a90700288" width="1" height="1" alt=""><hr><p><a href="https://medium.com/sbgrid-community-news/recognizing-the-worker-that-helps-package-herpesvirus-378a90700288">Recognizing the worker that helps package herpesvirus</a> was originally published in <a href="https://medium.com/sbgrid-community-news">SBGrid Community News</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Proteins at Work]]></title>
            <link>https://medium.com/sbgrid-community-news/proteins-at-work-f7d8bd90ae93?source=rss----4f09a70358f6---4</link>
            <guid isPermaLink="false">https://medium.com/p/f7d8bd90ae93</guid>
            <category><![CDATA[cryoet]]></category>
            <category><![CDATA[3d]]></category>
            <category><![CDATA[denoise]]></category>
            <category><![CDATA[sbgrid]]></category>
            <category><![CDATA[structural-biology]]></category>
            <dc:creator><![CDATA[SBGrid]]></dc:creator>
            <pubDate>Tue, 29 Sep 2026 14:11:01 GMT</pubDate>
            <atom:updated>2026-10-28T21:24:28.116Z</atom:updated>
            <content:encoded><![CDATA[<h4>Developer Tale</h4><h3><strong>Shawn Zheng</strong></h3><p><strong>Biohub</strong></p><p>Protein databanks are bursting with 3D structures that reveal molecules in vivid atomic details. But most of these molecules have been purified and studied in isolation, outside their native cellular environments. What researchers want to see now, in comparable detail, is how these molecules live and work together inside cells.</p><p>“The context-rich structural information, with molecular detail, is a cornerstone,” says software developer Shawn Zheng. “It is essential for understanding how a cell functions at the molecular level.”</p><figure><img alt="Headshot of Shawn Zheng" src="https://cdn-images-1.medium.com/max/600/1*AHZ4IiYwIVL4qIWI_2a44w.jpeg" /><figcaption>Shawn Zheng, Ph.D., Group Leader at CZI bi[o]hub</figcaption></figure><p>Based in Redwood City, California, Zheng leads an algorithm development team at Biohub, a nonprofit research organization launched by the Chan Zuckerburg Initiative in 2016. As its name suggests, Biohub brings together biologists, physicists, microscopists, and software and hardware engineers in a focused effort to develop breakthrough imaging technologies and methods.</p><p>Zheng and his colleagues focus on cryo-electron tomography (cryoET). The advanced imaging technique enables scientists to visualize the three-dimensional (3D) structures of cells and biomolecules at near-atomic resolution.</p><p>In fact, they predict cryoET will likely deliver the next major advance in structural and cellular biology. The push to see molecular details in their native environments comes on the heels of the resolution revolution of single-particle cryo-electron microscopy (cryoEM).</p><p>“CryoET not only reveals the high-resolution structures of biological molecules, but also preserves their original cellular context,” he says. “It feels like we’re on the eve of another revolution.”</p><p><strong>Challenges Abound</strong></p><p>Their computational efforts must overcome a harsh physical reality: CryoET seeks to reconstruct high-resolution 3D structures from noisy, incompletely sampled data from thick slices of biological samples that have been flash frozen to preserve a close-to native state.</p><p>These challenges begin as the microscope bombards the biological samples with a high-energy electron beam while gradually tilting them through a range of angles. CryoET captures a tilt series of 2D images to reconstruct a 3D volume, or tomogram.</p><p>Beam-induced motion and radiation damage further complicate this task. Low electron dose settings can limit radiation damage. Even so, beam-induced motion still deforms the sample and blurs the images, while imperfections in the microscope’s optics further distort the images.</p><p>Another challenge arises from a limitation in sample tilting. At higher angles, radiation damage accumulates, further reducing the high-resolution structural information needed to interpret molecular mechanisms. As a result, cryoET tilt series are typically collected over a limited angular range, leaving a gap known as the “missing wedge” in the data used to reconstruct a tomogram.</p><p><strong>Building Better Tomograms</strong></p><p>In their first two years at Biohub, Zheng’s team developed a computational solution to build better tomograms (<em>Nature Methods</em>, 2026). Called AreTomoLive, the software package enables fully automated, comprehensively corrected, and denoised cryoET reconstructions in real-time and at high throughput.</p><p>AreTomoLive cuts the processing timeline from several months to several days, or about 80 times faster according to an in-house estimate by Biohub biologists.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*YX465QJ0TzPnSvdhALTsVg.jpeg" /><figcaption>A simplified schematic of the AreTomoLive workflow shows key steps in the integrated and automated data preprocessing. First, AreTomo3 corrects for beam-induced motion and for microscope optics (known as contrast transfer function, or CTF). It also aligns the tilt series and reconstructs comprehensively corrected tomograms. In parallel, DenoisET, enhances the image (not pictured). Image courtesy S.Zheng and A.Peck.</figcaption></figure><p>Downstream processing can begin immediately rather than waiting for acquisition to finish. The integrated pipeline also eliminates the bottlenecks of moving data between software packages and formats for different preprocessing steps.</p><p>An experimentalist can put their sample on the microscope, identify all the positions they want to collect, start AreTomoLive, and walk away without having to worry about it, says Ariana Peck, a data scientist on Zheng’s team who led the AreTomoLive development.</p><p>AreTomoLive is composed of two GPU accelerated software packages seamlessly integrated together. The first, AreTomo3, reconstructs tomograms in real time with a lot of corrections built in for all the wacky things that happen in collecting data on biological samples on an electron microscope. It extends earlier software first developed by Zheng and colleagues at University of California, San Francisco, including the MotionCor2 and AreTomo series.</p><p>The other package, DenoisET, runs in parallel with AreTomo3. It implements the canonical Noise2Noise algorithm, a statistical insight that a denoising network can be trained using only noisy image pairs.</p><figure><img alt="Four figures: top left a weighted back-projection; top right denoised/AreTomo3-deconvolved; bottom left denoised/IsoNet-deconvolved; bottom right images combined with graph spatial frequency to relative power." src="https://cdn-images-1.medium.com/max/1024/1*nBFdWTXo3_Fh7WtUOcCn6w.jpeg" /><figcaption>Data collected in movie mode is denoised (right) to enhance the signal with 1.5 times more resolution than a stand-alone denoising software. Image courtesy S.Zheng and A.Peck.</figcaption></figure><p>AreTomoLive can keep up with recent advances in faster parallel data collection schemes. The two packages, AreTomo3 and DenoisET, are supported by SBGrid, with a webinar presentation by Peck available at <a href="https://sbgrid.org/software/titles/aretomo3.">https://sbgrid.org/software/titles/aretomo3.</a></p><p>For software users, Zheng fields ongoing questions and requests about features they would like to see and how to get the best performance from AreTomoLive for their data set and experimental setup.</p><p>“It’s a good collaboration with the community,” he says. “Many times, the questions are inspiring. From a purely software development perspective, they may present a new use case for your software and are very insightful.”</p><p><strong>Particle Picking</strong></p><p>The Biohub team has moved downstream to the next data processing hurdle in the cryoET workflow: to identify tens of thousands of copies of the target molecule in a crowded cellular environment across tens to many hundreds of tomograms.</p><p>It remains prohibitively difficult to find most protein species in the 3D reconstructions, a process known as particle picking, annotating or labeling. The task is plagued by a high false positive rate and noise artifacts that can smear the original structures, Zheng says.</p><p>They are exploring a range of machine-learning strategies to identify identical molecules across different conformations while distinguishing them from look-alike molecules of other species, known as dirty picks or false positives. Zheng and his colleague jokingly coined the term “computational purification” to separate clean picks from dirty picks. They now call the approach “computational distillation.”</p><p>In the overall cryoET workflow, particle picking sets up the final stage. Once the molecular targets have been identified, the target-rich parts of the tomograms are singled out for the high-resolution step of subtomogram averaging.</p><p>Subtomogram averaging (STA) is used to recover high-resolution structural information lost to the missing wedge. In this approach, researchers identify many copies of the same molecular complex across hundreds or thousands of tomograms and computationally align and average them. By combining information from large numbers of particles in different orientations, STA can compensate information missing from individual subtomograms while greatly enhancing the signal-to-noise ratio of the resulting maps.</p><p><strong>Casting a Wide Net</strong></p><p>Ultimately, biologists’ needs are the driving force behind the technology development, Zheng says. “But we also want to harness the collective brilliance of the community to advance these technologies, particularly against the backdrop of the dazzling advances of AI and machine learning.”</p><p>In 2025, Biohub launched a global competition to stimulate new machine learning algorithm development for particle picking. Hosted on Kaggle, the three-month challenge galvanized a large machine learning community, attracting more than 1,000 participants from 76 countries who submitted 28,000 solutions. (<em>Nature Methods</em>, 2026)</p><p>The data set for the contest was released on the CryoET Data Portal (<a href="https://cryoetdataportal.czscience.com/">https://cryoetdataportal.czscience.com/</a>), built in 2024 by a Biohub team to foster machine learning development using standardized data. The contest data, along with data contributed by in-house biologists, were reconstructed and denoised using AreTomoLive.</p><p>As cryoEM advanced in the 2010s, ribosome datasets became well known gold standard test cases for ever-sharper resolutions. Likewise, ribosomes are so commonly used to validate new cryoET methods at Biohub that the team jokes about “ribosome fatigue,” Zheng says, even though cryoET undoubtedly has much to reveal about this well-studied protein-building machinery in its native cellular context.</p><p><strong>Scientific Journey</strong></p><p>Zheng grew up in southeast China. He recalls starting school early and being the youngest kid in his class from elementary school through college. His father was a professor of material science at a local university. Zheng cites his father’s logic-based reasoning in conversations during his teenage years as a big influence that stoked his interest in a computation-related career.</p><p>After college, Zheng pursued a graduate degree in the United States. He earned his PhD in mechanical engineering from the University of Utah in 1999, focusing on the physics of fluids. He soon encountered a lean job market in experimental physics, prompting him to broaden the search to computational programming, based on the image processing skills he had developed through his physics experiments.</p><p>The first time he ever saw an electron microscope was in his job interview at UCSF with David Agard, who had an opening for a bioinformatics specialist. Agard became Zheng’s mentor for more than 20 years — longer than many marriages, Agard once joked.</p><p>At UCSF, Zheng supported Agard’s innovations in electron-counting detectors and beam-induced motion correction, advances that helped push cryoEM to atomic resolution. Despite these contributions to cryoEM, Zheng describes his career as being centered on cryoET. At UCSF, he also tackled the broader data processing challenges in cryoET, aiming to lower barriers for routine use by the nonexpert users, first with UCSFTomo and later with the MotionCor2 and AreTomo series.</p><p>Agard was the founding scientific director of what was then called the Chan Zuckerberg Imaging Institute, launched in 2022 and brought under the Biohub umbrella in 2025. He invited Zheng to join.</p><p>Zheng was drawn to the institute’s focus on developing new technology and new methods, its highly collaborative and supportive environment, and its in-house and extended network of expertise across technology fields. He takes additional inspiration from colleagues in different fields at Gordon Conferences and microscopy meetings. The Biohub further fosters this exchange through its residency program that brings together faculties and their graduate students and postdoctoral fellows from labs across the country and around the world, who regularly participate in online and in-person meetings on cryoET methods development.</p><p>Outside the lab, Zheng enjoys hiking with his wife and reading books about how high-achieving scientist leaders navigated difficult situations, such as Richard Feynman. He has a narrow range of favorite foods, yet many of which are easily available in the Bay Area, including fish and chips.</p><p><em>By Carol Cruzan Morton (</em><a href="https://medium.com/u/f67c2460605d"><em>carolmorton</em></a><em>)</em></p><p><em>Carol Cruzan Morton is a senior science writer and medical editor in Oregon. She contributes profiles to SBGrid and has also written for Science, Medscape, Oregonian, Boston Globe, and San Francisco Chronicle, among other publications.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=f7d8bd90ae93" width="1" height="1" alt=""><hr><p><a href="https://medium.com/sbgrid-community-news/proteins-at-work-f7d8bd90ae93">Proteins at Work</a> was originally published in <a href="https://medium.com/sbgrid-community-news">SBGrid Community News</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Monkeypox has no treatment. Scientists just found its weak spot.]]></title>
            <link>https://medium.com/sbgrid-community-news/monkeypox-has-no-treatment-scientists-just-found-its-weak-spot-8c396bd3d672?source=rss----4f09a70358f6---4</link>
            <guid isPermaLink="false">https://medium.com/p/8c396bd3d672</guid>
            <category><![CDATA[cryoem]]></category>
            <category><![CDATA[antivirals]]></category>
            <category><![CDATA[structural-biology]]></category>
            <category><![CDATA[monkeypox]]></category>
            <category><![CDATA[sbgrid]]></category>
            <dc:creator><![CDATA[SBGrid]]></dc:creator>
            <pubDate>Mon, 28 Sep 2026 16:31:01 GMT</pubDate>
            <atom:updated>2026-09-28T16:31:01.615Z</atom:updated>
            <content:encoded><![CDATA[<h4>Publication Highlight</h4><p><em>This publication highlight is part of the SBGrid Communities Project focused on science education and demonstrating how structural biology and preclinical science connect to medicine, a collaboration between SBGrid PI Piotr Sliz and Jamaine Davis of Belmont University.</em></p><p>One virus has caused two recent global outbreaks in two years, and it is not coronavirus. It’s the monkeypox virus (MPXV), and its outbreaks were serious enough that the World Health Organization (WHO) declared them both public health emergencies of international concern. Twice in two years: one in <a href="https://www.who.int/news-room/speeches/item/who-director-general-s-statement-on-the-press-conference-following-IHR-emergency-committee-regarding-the-multi--country-outbreak-of-monkeypox--23-july-2022">July 2022</a> for its outbreak in 75 countries and territories, another in <a href="https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern">August 2024</a> for its upsurge in the Democratic Republic of the Congo and neighboring countries. One virus, two separate emergency declarations, both recent enough that they’re still shaping how the world responds to outbreaks today.</p><p>Right now, there is <a href="https://www.cdc.gov/monkeypox/hcp/clinical-care/index.html">no FDA approved treatment</a> specifically for monkeypox. Although the <a href="https://www.fda.gov/vaccines-blood-biologics/jynneos">FDA has approved the JYNNEOS</a> vaccine for people at higher risk of exposure, there’s a catch. Prevention and treatment are not the same thing. Vaccines are preventative. They’re for people who have not been exposed yet, hoping they will not get the disease. When it comes to treating someone who’s already sick with monkeypox, there is no viable option yet.</p><p>This gap is why SBGrid member <strong>Jonathan Abraham</strong> and team at Harvard Medical School went searching for a different approach. They asked the question: how do viruses in this family assemble the machinery necessary to copy or replicate their DNA? Replicating its DNA is necessary for the MPXV virus to survive, and while many of the components or individual pieces involved are known, it was not clear how those pieces are assembled together. Understanding this process is important for the design of new treatments for people who become infected by MPXV.</p><p>Abraham and team used a technique called cryo-electron microscopy (cryo-EM) to watch how MPXV’s replication machinery actually works in 3D. Cryo-EM is similar to a camera, but instead of taking one photo, it flash-freezes thousands of copies of the same molecule, then photographs each one at the angles where frozen. A computer then combines the thousands of snapshots together into a 3D model.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/992/1*tBg8P6wjNN6YW5kPQDmJGA.png" /><figcaption>Surface representation of the MPXV replisome bound to single-stranded DNA (PDB: 9NSP) at 4.1 Å resolution. This image represents the moment the helicase and polymerase physically connect, prompting helicase activity. The E5 helicase hexamer is shown in gray, with one primase domain resolved separately (bottom left) because of its flexibility. The DNA polymerase holoenzyme (F8, A22, and E4) is shown in shades of green. The ssDNA is shown in purple, threading through the channel where the helicase and polymerase meet. Structure from Yu et al., 2026, rendered in ChimeraX. CC by SBGrid.</figcaption></figure><p>Using this technique, the researchers identified how the virus uses what is called a replisome, the machine that copies the virus’s DNA. They became the first to identify the interactions and actions of the helicase and polymerase, the two enzyme components responsible for key steps in the replication of this viral pathogen. This process allows us to visualize how the components of the replisome come together in various steps to copy the DNA.</p><p>Because of these new discoveries into how MPXV’s gears turn on, scientists now have more targets for future drug design. There is now a blueprint of where a treatment can intervene, particularly in the process of replication. The success of such a treatment looks promising because researchers have used a similar approach for treating herpes simplex virus (HSV1). <a href="https://www.nature.com/articles/s44259-026-00262-z">Pritelivir</a> recently completed a phase 3 trial as a successful inhibitor to a component of the DNA replication machinery in HSV1, stopping the virus from copying its own DNA. Our new understanding of how similar DNA machinery works in MPXV is opening the door for future monkeypox treatment.</p><p>Read more in <a href="https://www.nature.com/articles/s41586-026-10937-2"><em>Nature</em></a>.</p><p><em>By Vina Nguyen (</em><a href="https://medium.com/u/694b2aa9585c"><em>Vina Nguyen</em></a><em>), Lipscomb University</em></p><p><em>Vina Nguyen is an undergraduate student at Lipscomb University, pursuing a Bachelor’s degree in Molecular Biology and minors in Chemistry and Fashion Merchandising. Beyond the classroom, she enjoys trying new recipes, exercising, and exploring local coffee shops.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=8c396bd3d672" width="1" height="1" alt=""><hr><p><a href="https://medium.com/sbgrid-community-news/monkeypox-has-no-treatment-scientists-just-found-its-weak-spot-8c396bd3d672">Monkeypox has no treatment. Scientists just found its weak spot.</a> was originally published in <a href="https://medium.com/sbgrid-community-news">SBGrid Community News</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Bacterial Xenophilia: mechanisms behind foreign DNA import]]></title>
            <link>https://medium.com/sbgrid-community-news/bacterial-xenophilia-mechanisms-behind-foreign-dna-import-3b158a58ba3a?source=rss----4f09a70358f6---4</link>
            <guid isPermaLink="false">https://medium.com/p/3b158a58ba3a</guid>
            <category><![CDATA[sbgrid]]></category>
            <category><![CDATA[bacteria]]></category>
            <category><![CDATA[antibiotic-resistance]]></category>
            <category><![CDATA[dna]]></category>
            <category><![CDATA[structural-biology]]></category>
            <dc:creator><![CDATA[SBGrid]]></dc:creator>
            <pubDate>Sun, 27 Sep 2026 14:58:34 GMT</pubDate>
            <atom:updated>2026-09-27T14:58:32.980Z</atom:updated>
            <content:encoded><![CDATA[<h4>Publication Highlight</h4><p><em>This publication highlight is part of the SBGrid Communities Project focused on science education and demonstrating how structural biology and preclinical science connect to medicine, a collaboration between SBGrid PI Piotr Sliz and Jamaine Davis of Belmont University.</em></p><p>Antibiotic resistance is a growing global health concern, and one driver of this growth is natural transformation, a process by which bacteria take in outside DNA and add it to their genome. There are two proteins directly involved in this process: ComEA, a receptor that binds the outside DNA, and ComEC, a membrane protein that is responsible for bringing single stranded DNA (ssDNA) into the cell. ComEC has a B-lactamase-like domain. Although B-lactamase traditionally breaks down Beta-lactam antibiotics like penicillin, the B-lactamase-like domain in ComEC is responsible for binding and breaking down DNA. This knowledge was confirmed by structure analysis of the isolated B-lactamase-like domain in prior studies; however, it remains unclear <em>how</em> ComEC selectively separates the strands and moves the now single-stranded DNA into the cell and <em>if</em> ComEA plays a part in the process. In a recent <em>Nucleic Acids Research</em> article, SBGrid member <strong>Manuela Hospenthal </strong>and researchers at ETH Zürich describe the mechanisms by which full-length ComEC from <em>Neomoorella carboni</em>s transports ssDNA and how its related receptor, ComEA, mediates this process.</p><p>Full-length ComEC from<em> Neomoorella carbonis </em>(ComECNC) has three domains: B-lactamase-like domain, oligonucleotide binding domain (OB fold), and a competence domain containing 11 transmembrane helices (TM1-TM11). TM4–9 forms a narrow channel that needs to go through shape changes to accommodate the incoming ssDNA. Researchers decided to use AlphaFold3 to model ComECNC bound to ssDNA and compared it to full-length ComECNC in a closed, unbound state. Doing so led to the hypothesis that activation leads to an inner loop (NS4-TM4 loop) and causes the membrane helices (TM4–6) to shift, leading to a wider and straightened channel that allows the passage of ssDNA. Because ComECNC is a membrane protein, there is a chance that these structural characteristics are for selective passage and transport of ssDNA. Upon investigating the suspected transport complex, they found that the NS4-TM4 loop contains several bulky amino acids, like H254 (histidine), partially blocking the channel and acting as gates. H254 was found to have two orientations, one of which reflects the predicted orientation changes that would come with channel opening and allowing the transport of ssDNA.</p><p>Comparison of previously determined structures with ComECNC illustrated that the B4-B5 loops of the OB-fold domain have a short helix that touches the Beta-lactamase-like domain. This shared domain interface provides flexibility and enough strength to keep the two in proximity. Comparison across species confirms that the loop is preserved, but other species have additional residues contributing to overall shape and stability. It is possible that the proximity of the OB-fold and the stability it provides facilitates DNA attachment to ComECNC and allows full-length ComECNC to break down DNA better than the B-lactamase-like domain by itself.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*kc36cS4yqlE9hYbxRxMdDQ.png" /><figcaption><strong>Top</strong>: Monomeric ribbon view of full length ComEC from <em>Neomoorella carbonis</em> (ComECNC) unbound, with Beta-lactamase-like domain, competence domain, and OB-fold highlighted in sky blue, light teal, and salmon (PDB 32KS). <strong>Bottom left</strong>: B4-B5 loops are highlighted in magenta in this superimposed view of the loops; here you can see the short alpha helix that forms an interface with the Beta-lactamase-like protein. The bulky residues, which form a another tshort helix, are higlighted in yellow, with H254 being highglihted in navy blue. <strong>Bottom right</strong>: The surface image depicts H254’s ability to act as a “gate” to the channel. (CC by SBGrid).</figcaption></figure><p>Complete understanding of how ComEC allows DNA passage through the membrane requires understanding how the double stranded DNA (dsDNA) is initially presented to ComEC. ComEA receptors bind to and surround the double stranded DNA; in doing so they cover the internal regions of the strand. At this point ComEC attaches to the end of one strand then breaks the strand piece by piece, still allowing transport of the other strand of DNA across the cellular membrane. Without the ComEA receptors protecting the middle regions of the strand, ComEC would randomly break down both strands instead of one.</p><p>Altogether, researchers at ETH Zurich found that the B-lactamase-like domain is responsible for breaking down DNA, the competence domain forms the channel and, along with the OB-fold domain, aids in the passage of DNA through the cell membrane. Additionally, researchers found that the complementary ComEA receptors not only bind the dsDNA, but also protect the middle regions of the DNA strand, guiding ComEC binding and cutting and allowing natural transformation to occur.</p><p>Understanding how processes like natural transformation occur can help scientists combat antibiotic resistance and could improve or save many lives.</p><p>Read more in <a href="https://academic.oup.com/nar/article/54/16/gkag861/8780934?login=false"><em>Nucleic Acids Research</em></a></p><p><em>By Cariuna M. Ellison (</em><a href="https://medium.com/u/b8a86fe2142b"><em>Cariuna Ellison</em></a><em>), Fisk University</em></p><p><em>Cariuna M. Ellison is an undergraduate student at Fisk University, pursuing a Bachelor’s degree in Biochemistry and Molecular Biology. She is on track to graduate in May 2028. In her free time, she enjoys reading, exercising, and giving back to her community in any way she can.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=3b158a58ba3a" width="1" height="1" alt=""><hr><p><a href="https://medium.com/sbgrid-community-news/bacterial-xenophilia-mechanisms-behind-foreign-dna-import-3b158a58ba3a">Bacterial Xenophilia: mechanisms behind foreign DNA import</a> was originally published in <a href="https://medium.com/sbgrid-community-news">SBGrid Community News</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The not so easy job of protecting our DNA]]></title>
            <link>https://medium.com/sbgrid-community-news/the-not-so-easy-job-of-protecting-our-dna-ed884efea725?source=rss----4f09a70358f6---4</link>
            <guid isPermaLink="false">https://medium.com/p/ed884efea725</guid>
            <category><![CDATA[atr-inhibition]]></category>
            <category><![CDATA[structural-biology]]></category>
            <category><![CDATA[dna-repair]]></category>
            <category><![CDATA[cancer-research]]></category>
            <category><![CDATA[sigrid]]></category>
            <dc:creator><![CDATA[SBGrid]]></dc:creator>
            <pubDate>Fri, 28 Aug 2026 00:41:01 GMT</pubDate>
            <atom:updated>2026-08-28T00:41:01.178Z</atom:updated>
            <content:encoded><![CDATA[<h4>Publication Highlight</h4><p><em>This publication highlight is part of the SBGrid Communities Project focused on science education and demonstrating how structural biology and preclinical science connect to medicine, a collaboration between SBGrid PI Piotr Sliz and Jamaine Davis of Belmont University.</em></p><p>Our cells are more than automated machines simply executing a fixed set of instructions. They are dynamic, making decisions based on the conditions around them. The DNA damage mechanism is no different. For years, studies suggested that ATR, which is a protein kinase essential for protecting our DNA from damage, functioned much like a molecular light switch, turning on in response to replication stress and off once the threat had passed. Recent findings from <strong>SBGrid member Nikola Pavletich</strong> and team at Memorial Sloan Kettering Cancer Center reveal that the ATR mechanism is much more nuanced.</p><p>ATR preserves the integrity of our genome by carrying the catalytic mechanisms that control responses to DNA replication stress and checkpoints for the progression of the S phase in the cell cycle. ATR does not function alone. It has an essential partner that helps to stabilize the overall structure named ATRIP, and these proteins exist and function together in what is called the ATR-ATRIP complex. ATR, in the ATR-ATRIP complex, is activated by two known proteins: TOPBP1 and ETAA1. These two proteins allow ATR to not just flip on and off. They give ATR the ability to read its environment. Depending on different levels of stress, ATR answers with different levels of urgency.</p><p>Structurally, TOPBP1 and ETAA1 are large multi-domain proteins. Their ability to activate ATR is dependent on a ~200 amino acid segment in their overall structure named ATR activating domains (AADs). Despite activating the same ATR, TOPBP1 and ETAA1 look completely unrelated with low sequence homology. The only similarity in these AADs are two conserved residues. This process led researchers to ask: how can two seemingly dissimilar proteins, with low sequence homology, trigger the same kinase? To answer this question, researchers reconstructed the human ATR-ATRIP complex bound to isolated AADs of TOPBP1 and ETAA1 and solved their structures using cryo-EM at 3.0 Å resolution.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*bWiLhDvU1vCvlI2_JndQww.png" /><figcaption>Left: Surface representation of the ATR-ATRIP complex on its own (PDB: 9ZCY) at 2.50 Å resolution, before it is activated by TOPBP1 or ETAA1. ATR is shown in tan and ATRIP is shown in purple. Structure from Li et al., 2026, rendered in ChimeraX. CC by SBGrid. Right: Surface representation of ATR-ATRIP bound to TOPBP1’s ATR activating domain (PDB: 9ZD1) at 3.20 Å. ATR is shown in tan, ATRIP in purple, and TOPBP1’s ATR activating domain in green. Compared to the inactive ATR-ATRIP complex, TOPBP1 binding causes the complex to physically change shape, switching ATR into its active form. Structure from Li et al., 2026, rendered in ChimeraX. CC by SBGrid.</figcaption></figure><p>Analyzing the structural interactions of TOPBP1 and ETAA1 with ATR allowed the researchers to measure two factors: binding (how well the individual activators stick to ATR) and activation (how well does the ATR kinase become activated to function). When measuring kinase activity, TOPBP1 increased ATR activity by ~100-fold while ETAA1 only increased ATR activity by ~5-fold. They also found that two of ETAA1’s contact points physically overlap where TOPBP1 needs to bind, meaning that ETAA1 is also a competitive blocker.</p><p>These differences in ATR activity align with the differing roles these activator proteins play in the cell. Under normal conditions, a cell will experience minor, everyday DNA mechanistic errors. ETAA1 will activate ATR to upkeep routine progression of the cell cycle to ensure a smooth process. However, under acute stress, TOPBP1 will instead activate ATR to act as an emergency brake. When the DNA replication fork stalls, TOPBP1-activated ATR will pause the cell cycle so DNA can repair before dividing. Because ATR is not a simple on and off switch, it is important to understand the mechanism structurally to know where and how ATR can be inhibited or activated.</p><p>These new understandings matter because ATR-ATRIP has become a major target in cancer therapy. Cancer cells want to divide rapidly, often leading to mutations and large amounts of DNA replication stress. Despite this constant stress, cancer cells are surviving because ATR is working overtime to manage the damage. Understanding exactly how ATR gets turned on can tell researchers how to precisely turn it off, potentially targeting the cancer cells while leaving healthy cells intact.</p><p>TOPBP1 and ETAA1 structures and mechanisms show that different DNA stress triggers different responses to proteins. Even at the molecular level, there is more nuance than simply on and off. Our cells have the ability to adjust to different levels of stress and different proteins will show up depending on that level. Currently, ATR inhibitors are being tested in multiple clinical trials for various cancers, including trials in <a href="https://clinicaltrials.gov/study/NCT04616534">pancreatic and ovarian cancer</a>, <a href="https://clinicaltrials.gov/study/NCT03787680">prostate cancer</a>, <a href="https://clinicaltrials.gov/study/NCT04065269">gynaecolical cancers</a>, and <a href="https://clinicaltrials.gov/study/NCT03896503">small cell lung cancers</a>. Understanding the nuanced activation mechanism and structure of ATR opens the opportunity for more precise approaches and less harmful side effects in cancer treatments.</p><p>Read more in <a href="https://www.nature.com/articles/s41594-026-01844-1"><em>Nature Structural and Molecular Biology</em></a></p><p><strong>By Vina Nguyen</strong>, <em>Lipscomb University </em>(<a href="https://medium.com/u/694b2aa9585c">Vina Nguyen</a>)</p><p><em>Vina Nguyen is an undergraduate student at Lipscomb University, pursuing a Bachelor’s degree in Molecular Biology and minors in Chemistry and Fashion Merchandising. Beyond the classroom, she enjoys trying new recipes, exercising, and exploring local coffee shops.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=ed884efea725" width="1" height="1" alt=""><hr><p><a href="https://medium.com/sbgrid-community-news/the-not-so-easy-job-of-protecting-our-dna-ed884efea725">The not so easy job of protecting our DNA</a> was originally published in <a href="https://medium.com/sbgrid-community-news">SBGrid Community News</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Antibodies guiding cancer immunotherapy]]></title>
            <link>https://medium.com/sbgrid-community-news/antibodies-guiding-cancer-immunotherapy-d56f254c79c0?source=rss----4f09a70358f6---4</link>
            <guid isPermaLink="false">https://medium.com/p/d56f254c79c0</guid>
            <category><![CDATA[immune-system]]></category>
            <category><![CDATA[cancer]]></category>
            <category><![CDATA[sbgrid]]></category>
            <category><![CDATA[structural-biology]]></category>
            <category><![CDATA[antibody]]></category>
            <dc:creator><![CDATA[SBGrid]]></dc:creator>
            <pubDate>Thu, 27 Aug 2026 23:41:01 GMT</pubDate>
            <atom:updated>2026-08-27T23:41:01.684Z</atom:updated>
            <content:encoded><![CDATA[<h4>Publication Highlight</h4><p><em>This publication highlight is part of the SBGrid Communities Project focused on science education and demonstrating how structural biology and preclinical science connect to medicine, a collaboration between SBGrid PI Piotr Sliz and Jamaine Davis of Belmont University.</em></p><p>Cancer is a multifactorial disease characterized by uncontrolled cell growth with a broad range of treatment strategies. While some of the better known therapies include surgical tumor resection, radiation, and chemotherapy, another option is chimeric antigen receptor T cell immunotherapy, or CAR T therapy. The immune system, our primary defense against foreign threats — bacteria, viruses, and even cancer — includes many types of cells: T cells, B cells, and more. For CAR T therapy, a collection of T cells are isolated, exposed to an antigen that the cancer cells are expected to produce, and re-introduced into the body to launch a more focused attack against the cancer cells. One drawback of this approach is the possibility for the T cells to attack healthy cells along with cancerous ones, leading to off-target toxic effects. Furthermore, tumor cells can activate the programmed cell death (PD-1) pathway in T cells to avoid being killed by the host immune system. To prevent these consequences, PD-1 blockers may be added to the treatment protocol for a patient with cancer. Plasma cells are a type of B cell, primarily responsible for generating antibodies in response to an antigen. Previous work has revealed that there are B cells which invade a tumor, and that increased frequency of intratumoral plasma cells that express CD138 proteins on their cell surface has been associated with better outcomes after treatment with a PD-1 blocker in patients with non-small cell lung cancer (NSCLC). Currently, the specific anti-tumor activity of infiltrating plasma cells has not been clarified.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1002/1*EsypNsthjpZovNbDGBQzFg.png" /><figcaption>Scanning electron micrograph image of T lymphocyte (T cell). Courtesy of Unsplash (<a href="https://unsplash.com/photos/a-close-up-of-a-white-substance-on-a-blue-background-5v0UyRolNwg">https://unsplash.com/photos/a-close-up-of-a-white-substance-on-a-blue-background-5v0UyRolNwg</a>).</figcaption></figure><p>SBGrid member Priyamvada Acharya contributed to a paper with colleagues at Duke University School of Medicine that explores how utilizing a component of the innate immune response, the tumor infiltrating plasma cells and they antibodies they produce, can inform the CAR T cancer immunotherapy approach. The researchers used single-cell RNA sequencing to look at the antibodies produced by tumor infiltrating B cells (TIL-Bs). They discovered that the antibodies produced by various TIL-Bs reacted to proteins made by NSCLC tumor cells, but not normal cells. This result is promising for limiting the amount of off-target toxicity. To examine this reaction further, they isolated one of the tumor-responsive antibodies, PC-1, produced by TIL plasma cells to train the CAR T cells for use in NSCLC patients treated with a PD-1 blocker. They found that the CAR T cells successfully killed tumor cells and tumor-promoting myeloid cells without off-target toxicity. Furthermore, they found that the PC-1 antibodies bound to citrullinated antigens vimentin, Hsp90, p53, and calreticulin, expressed on the surface of cancer- and tumor-promoting myeloid cells. Citrullination is a modification to a protein that may occur in the setting of cellular stress where an arginine residue is converted to citrulline. Although citrullination also occurs transiently in normal cells, the chronic inflammatory, hypoxic, and cellular stress state present within tumor cells may explain why citrullination of the tumor and pre-tumor myeloid cells were uniquely identified by the PC-1 antibodies. This research provides insight into potential therapeutic CAR T and cancer vaccination approaches using antibodies generated by TIL-Bs. The structure of the PC-1 antibody bound to citrullinated vimentin has yet to be characterized, likely due to structural flexibility, and thus preventing concrete structural determination. Future work may be geared toward increasing the sample size of clinical tumor specimens, which may increase the diversity of antibodies produced by TIL-Bs.</p><p>Read more about this work in <a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(26)00310-7"><em>Cancer Cell</em></a>.</p><p><em>By Mudiare Ikoba (</em><a href="https://medium.com/u/bde221712474"><em>Mudia Ikoba</em></a><em>), Meharry Medical College</em></p><p><em>Mudiare “Mudia” Ikoba is a second-year medical student at Meharry Medical College. She completed her B.A. in Biology with a Biochemistry Concentration and a minor in Social Inequalities at Dartmouth College. When she is not studying, she enjoys being outdoors, exercising, cooking, and spending time with family and friends.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d56f254c79c0" width="1" height="1" alt=""><hr><p><a href="https://medium.com/sbgrid-community-news/antibodies-guiding-cancer-immunotherapy-d56f254c79c0">Antibodies guiding cancer immunotherapy</a> was originally published in <a href="https://medium.com/sbgrid-community-news">SBGrid Community News</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Brake-ing Down Protein Activation and Signaling]]></title>
            <link>https://medium.com/sbgrid-community-news/brake-ing-down-protein-activation-and-signaling-702ab8acbceb?source=rss----4f09a70358f6---4</link>
            <guid isPermaLink="false">https://medium.com/p/702ab8acbceb</guid>
            <category><![CDATA[diabetes]]></category>
            <category><![CDATA[sbgrid]]></category>
            <category><![CDATA[protein]]></category>
            <category><![CDATA[signaling]]></category>
            <category><![CDATA[structural-biology]]></category>
            <dc:creator><![CDATA[SBGrid]]></dc:creator>
            <pubDate>Thu, 27 Aug 2026 22:31:01 GMT</pubDate>
            <atom:updated>2026-09-27T14:53:28.145Z</atom:updated>
            <content:encoded><![CDATA[<h4>Publication Highlight</h4><h3>Brake-ing down protein activation and signaling</h3><p><em>This publication highlight is part of the SBGrid Communities Project focused on science education and demonstrating how structural biology and preclinical science connect to medicine, a collaboration between SBGrid PI Piotr Sliz and Jamaine Davis of Belmont University.</em></p><p>Far beyond being nutrients, proteins are intricate molecules that wear many hats within cells, enabling your body to do everything it needs to.<strong> </strong>Receptor tyrosine kinases (RTKs) are proteins on the cell surface that are important in signaling and regulating many cellular processes. The most notable RTK is the insulin receptor (IR), which, when defective, can contribute to insulin resistance and subsequently type 2 diabetes. Other RTKs, like the epidermal growth factor receptor (EGFR), are important in the development and progression of various cancer types, including lung, breast, and prostate cancers. Although IR- and EGFR-family receptors are well studied, the mechanisms driving EGFR signaling remain unclear. It was previously believed that a ligand binds and activates EGFR through the formation of a single unit (a dimer) from two distinct receptors (dimerization); however, the presence of “preformed” dimers without a ligand catalyst has left scientists confused about the true mechanisms of activation. Building on previous observations of the extracellular region of EGFRs, Kate Ferguson and fellow researchers from the Yale University School of Medicine used cryo-EM to determine the structure and elucidate the mechanism of activation using an EGFR from the model organism Caenorhabditis elegans, LET-23.</p><p>Preformed dimers have five domains within each receptor, with domains 2 and 4 contributing significantly to the binding interface, and a dimer arm connecting domains 2 and 3 of both receptors. Additionally, domain 5 contains a long leg on each receptor, equaling a distance of about 200 Angstroms between the two in its inactive state, which effectively prevents the intracellular kinase regions from interacting and LET-23 activation. Next, researchers examined how LET-23 would act once bound to its activating ligand, LIN-3. It was found that the legs of domain 5 were brought within 30 Angstroms of each other and then allowed activation. Altogether, as with the IR receptor family, LET-23 initially inhibits interactions between its intracellular kinase regions until the ligand binds, allowing receptor activation.</p><p>In the activated ligand-bound form, domain 2 interacts with domain 4 in the inactive preformed dimer for stability, but switches its interactions to domain 5. As this occurs, the legs of domain 5, which we now know come closer in proximity, also switches from right leg crossing left to left leg crossing over right. Though domain 4 loses its role in the ligand-bound form, it is important to note that it contains 9 residues, spanning from residues 594–602 and forming a dimer loop, that when deleted, completely breaks the preformed dimer into two separate receptors. These receptors can still be joined and activated by binding LIN-3, indicating that the existence of preformed dimers does inherently hinder LET-23’s activation.</p><p>To verify the importance of this newly discovered domain 4 loop and its effect on LET-23, researchers performed a study involving purposefully deleting the domain 4 loop to separate the preformed dimers, to determine if preformed dimers inhibit LET-23 activation. Results indicated no inhibition with the loop deleted and leading to to the conclusion that eliminating preformed dimers does not interfere with LET-23 activation. Through another series of experiments in which mutations were introduced to the domain 4 loop, researchers concluded that the preformed dimers act almost like a dial, tuning LET-23’s sensitivity and its resulting signaling.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*cb-FEbA44P95myki5oU9cA.png" /><figcaption>Left: Inactive dimer of the C. elegans EGFR (LET-23) bound to LIN-3 with the domain 2 “arm,” domain 4 loops, and domain 5 legs highlighted in mustard yellow, pink, and light blue respectively (PDB 9YOT). The right leg crosses over the left and the distance is about 200 Angstroms. CC by SBGrid. Right: Active dimer of the C. elegans EGFR (LET-23) bound to LIN-3 with the domain 2 “arm,” domain 4 loops, and domain 5 legs highlighted in mustard yellow, pink, and light blue respectively (PDB 9YOS). There is now some overlap within the domain 2 arm, as shown by the gray colored residues slightly covering it. Additionally, here, the left leg crosses over the right and the distance is notably smaller at about 30 Angstroms. CC by SBGrid</figcaption></figure><p>After performing cryo-EM and analyzing the data, researchers concluded that LET-23 existed in two primary conformations, outside of its state as an inactive preformed dimer: a ligand-bound inactive state and a ligand-bound active state. In the ligand-bound inactive state, domain 4 interactions remain intact, keeping the intracellular kinases from meeting and the receptor from activating. In the ligand-bound active state, domain 4 interactions break and allow the intracellular kinases to come together and trigger signaling. Altogether, domain 4 acts as an autoinhibitory brake that must be broken by ligand, or LIN-3, binding.</p><p>In this study, researchers clarified and contributed to the mechanisms underlying EGFR family activation through cryo-EM analysis of an EGFR from C. elegans, LET-23. Previously believed to differ, both the IR and EGFR families have a way of hindering activation initially, with EGFRs doing so through the presence of the domain 4 loop. And finally, the binding of LIN-3 breaks this loop, allowing the intracellular kinase domains to come together and LET-23 to become active. From these parallels, researchers concluded that the results of LET-23 may provide a structural map for identifying a missing evolutionary link between the IR and EGFR families that enables their activation.</p><p>With RTKs being linked to diseases that affect so many worldwide, like various cancer types and diabetes, they have become a major focus for drug development. Understanding the structural mechanisms these proteins undergo to activate and signal allows others to identify small molecules that may inhibit or enhance RTK activity.</p><p>Read more in <a href="https://doi.org/10.1073/pnas.2602436123"><strong><em>PNAS</em></strong></a>.</p><p><em>Cariuna M. Ellison (</em><a href="https://medium.com/u/b8a86fe2142b"><em>Cariuna Ellison</em></a><em>), Fisk University</em></p><p><em>Cariuna M. Ellison is an undergraduate student at Fisk University, pursuing a Bachelor’s degree in Biochemistry and Molecular Biology. She is on track to graduate in May 2028. In her free time, she enjoys reading, exercising, and giving back to her community in any way she can.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=702ab8acbceb" width="1" height="1" alt=""><hr><p><a href="https://medium.com/sbgrid-community-news/brake-ing-down-protein-activation-and-signaling-702ab8acbceb">Brake-ing Down Protein Activation and Signaling</a> was originally published in <a href="https://medium.com/sbgrid-community-news">SBGrid Community News</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Viruses for Good]]></title>
            <link>https://medium.com/sbgrid-community-news/viruses-for-good-ec22f0f763e2?source=rss----4f09a70358f6---4</link>
            <guid isPermaLink="false">https://medium.com/p/ec22f0f763e2</guid>
            <category><![CDATA[volume-microscopy]]></category>
            <category><![CDATA[virus]]></category>
            <category><![CDATA[bacteriophages]]></category>
            <category><![CDATA[structural-biology]]></category>
            <category><![CDATA[sbgrid]]></category>
            <dc:creator><![CDATA[SBGrid]]></dc:creator>
            <pubDate>Thu, 27 Aug 2026 21:26:23 GMT</pubDate>
            <atom:updated>2026-08-27T21:44:12.226Z</atom:updated>
            <content:encoded><![CDATA[<h4>Member Tale</h4><h3>Mihnea Bostina</h3><p><strong>University of Otago</strong></p><p>Viruses are usually studied as villains. After all, they can spread disease and death, disrupt society, and destroy crops. Fewer people look to them as allies. But viruses aren’t all bad. Some may have the power to clear infections and fight tumors.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/798/1*xBilG0VnMhkbgmeLN9eC5w.png" /><figcaption>Prof. Mihnea Bostina, University of Otago</figcaption></figure><p>In his New Zealand laboratory, Mihnea Bostina wants to understand and harness the therapeutic potential lurking in some viruses to treat people and plants. “We work with a lot of viruses, mostly good viruses,” he says.</p><p>One virus the lab studies selectively infects and kills certain tumor cells, while sparing healthy tissue. The group also works with bacteriophages, a type of virus that infects only bacteria, raising hopes that one day it may help overcome the problem of antibiotic resistance. For these studies, the lab deploys cryo-electron microscopy (cryoEM), which comprises about half of the lab’s work.</p><p>CryoEM took center stage in structural biology methods when it broke through to atomic resolution, but the other half of the Bostina lab is zooming out with an emerging technique known as volume electron microscopy (vEM). They are exploring more life-like 3D tissue models of cancer and viral infections to gather structural information at a resolution that bridges traditional cell and structural biology. “It’s better than light microscopy, but not as good as cryoEM,” he says.</p><p><strong>Virus versus tumors</strong></p><p>Bostina has been captivated by viruses since his earliest days as a scientist. “Structurally, they have these beautiful symmetries,” he says. “And it was an interesting question: How do those proteins know to self-assemble with such precision in certain conditions, and in such stable protein cages, which are almost indestructible by pH and temperature.</p><p>“They can resist a lot of chemical and physical factors, and suddenly, when the right moment occurs, the right receptor, the same solid, beautiful symmetrical structure disassembles and delivers the genome, and rapidly takes over the cells,” he says.</p><p>Bostina helped identify the tumor receptor for the anti-cancer virus, Seneca Valley Virus (SVV-001), which seems most attracted to neuroendocrine tumors, such as small-cell lung cancer. The discovery of the receptor suggested a way to screen for patients more likely to benefit. A clinical study by US researchers is underway in Miami.</p><p>The lab’s subsequent structural studies of SVV-001 have helped explain how the virus homes in on a receptor protein overexpressed in tumors (TEM8, also known as anthrax toxin receptor 1) and not on a similar protein in healthy cells. (<em>PNAS</em>, 2018) More recent studies have revealed how the virus enters the tumor cell and delivers its genome. (<em>Journal of Virology</em>, 2025)</p><p>In one barrier for effective treatment, oncolytic virus strategies are short-lived. “The problem with all these viruses is that the body develops antibodies,” he says, “so there is a lot of interest in trying to give these good viruses a better chance to kill the tumor. We’re working a bit with that.”</p><p><strong>Viruses versus bacteria</strong></p><p>As multi-drug-resistant bacteria spread, due to overuse and misuse of antibiotics, interest in bacteriophages has grown as a possible solution. Until recently, phages were difficult to study, because they have large, complicated architectures that are difficult to decipher in atomic detail. But now “microscopes are better, software is faster, and people are more enthusiastic,” he says. “Now it’s a kind of avalanche of new structures.”</p><p>The family of phages Bostina’s team studies are the largest collection of viruses on the planet. The phages pack their genes into soccer-ball-like capsids with tail machinery that injects their DNA into specific bacteria. The capsids are made of many copies of identical proteins. The major capsid protein itself varies from phage to phage, but all tailed phages share a famous 3D fold named HK97. The identical capsid proteins adopt subtle variations on the core HK97 fold to construct and close the icosahedral cages.</p><p>The team has collaborated with researchers from overseas laboratories on several structures. They are looking at how the proteins regulate the tail injection mechanism and what prompts the sudden structural changes. They aim to build models to tease out universal principals about how phages interact with their bacterial hosts and also to understand the idiosyncrasies of specific phage infections.</p><p>One study in collaboration with Okinawa Institute of Science and Technology in Japan looked at a bacteriophage (phiTE) that infects a potato plant pathogen. The bacterium <em>Pectobacterium atrosepticum</em> causes stems to blacken, tissues to decay, and often leads to plant death, resulting in significant agricultural losses each year. The study provided a structural atlas of the phage and may inform rational design of biocontrol agents against plant pathogens that cause diseases such as soft rot and blackleg disease in potatoes, the team notes. (<em>Nature Communications</em>, 2025)</p><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fwww.youtube.com%2Fembed%2F6lO4_5h5Vd4%3Ffeature%3Doembed&amp;display_name=YouTube&amp;url=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3D6lO4_5h5Vd4&amp;image=https%3A%2F%2Fi.ytimg.com%2Fvi%2F6lO4_5h5Vd4%2Fhqdefault.jpg&amp;type=text%2Fhtml&amp;schema=youtube" width="640" height="480" frameborder="0" scrolling="no"><a href="https://medium.com/media/901258b7084a80cc415137b0b4c3c64d/href">https://medium.com/media/901258b7084a80cc415137b0b4c3c64d/href</a></iframe><p>Another study looked at Bas63, a phage that infects <em>E. coli</em> bacteria. It is related to a phage that infects salmonella that has been engineered into a biodetection tool for detecting salmonella in food samples. Bostina and his colleagues chose Bas63 for its unique genome and were able to match protein shapes to previously unannotated genetic codes. Overall, the phage features structural elements found in three distant families of phages. (<em>Science Advances</em>, 2025)</p><p>“It was very interesting to find that the general architecture of the bacteriophage are in many ways identical in a lot of related viruses, but they are very, very different in the regions which recognize the receptor, which gives us hope that we can take the bacteriophage, understand the structure very well, and after that modify only a little part to make it specific to a certain bacteria.”</p><p>The bacteria will mutate to resist the phage, but scientists can identify the domain and engineer a mutation that compensates and enables the phage to continue to fight the bacteria. This is something structural biologists do for all types of treatments, Bostina notes.</p><p>“We have solved so many phage viruses that we have started to understand that there are certain little domains, certain little loops, and certain little termini, which are regulating that conformational change, and there are other little proteins that are stabilizing those structures,” he says. “It’s an avalanche of conformational change, which has to come exactly in the right succession for the infections. They are very dynamic.”</p><p><strong>Around the World with CryoEM</strong></p><p>Bostina grew up in Romania, the son of humanities professors. His mother specialized in Greek and Latin, and his father in French. The former communist country emphasized science over other subjects during his school years. “Basically everybody did math or physics,” says Bostina, who graduated University of Bucharest with a degree in each.</p><p>He started doctoral studies in environmental science in Bucharest but reconsidered and headed to the Max Planck Institute of Biophysics in Frankfurt. He earned his PhD using cryo-electron microscopy to study membrane proteins in the lab of Werner Kühlbrandt, who later coined the term “resolution revolution.” Bostina stayed for a short postdoctoral fellowship.</p><p>In 2005, he began the first of westward moves, stopping in Boston for five years to apply cryoEM to polio virus studies in the lab of James Hogle at Harvard Medical School. In 2010, he moved to McGill University in Montreal, where they installed one of the first of the new generation of powerful electron microscopes. “This was before the introduction of direct detectors, still in the ‘blobology’ era of electron microscopy,” Bostina says.</p><p>In 2013, he moved to New Zealand to join the faculty at the country’s oldest university. There he also leads the microscopy center with 21st century microscopy instruments while experiencing an academic life with the free-ranging intellectual breadth reminiscent of an earlier era.</p><p>University of Otago is located in the coastal city of Dunedin on the larger South Island, where about one-quarter of the NZ population are spread over more than half the country’s land mass. The eastern tip of the peninsula that forms the town’s harbor shelters the only mainland breeding colony of Royal Albatross, the world’s largest birds with a three-meter wingspan. “They are by far my favorite birds,” he says. The land rises quickly to the mountains where NZ mountaineer Sir Edmund Hillary trained for his historic summit of Mt. Everest.</p><p>From campus, Bostina can drive home a few miles one direction where he shares his rural property with sheep or a few miles the other direction to see a concert or sip excellent coffee at one of the cafes in town.</p><p>The small population, remote location and distinctive ecosystems combine to give research in New Zealand “a bit of the charm and the flavor of the 19th century sciences, because you always are in contact with all scientists, who are doing completely different things,” Bostina says.</p><p>It’s an interesting contrast to the scientific centers of Harvard, McGill and Max Planck where he trained and first worked, he says. “Of course, this is a challenge on a scientific level, because you don’t interact with people who understand and can advise you on your work, but you always gain something when you lose something.”</p><p><strong>Mind the Gap</strong></p><p>In New Zealand, Bostina became interested in volume microscopy (vEM), which “fills the gap” between light microscopy and structural biology. Dubbed the “quiet revolution” (<em>Nature</em>, 2023), vEM can probe the 3D structures of tissue, from organelles within cells to communities of cells within tissue. It was originally used to examine connections and activity of neurons in the brain.</p><p>“We’re trying to understand the ultrastructure of biopsies of cancer,” he says. The team is working with 3D cultures of cell lines and with patient biopsies. Ultimately, they want to know why some of the same cancers in different people respond to the same treatment, while others do not. He predicts the vEM data will supplement other clinical diagnostic and prognostic measures, such as genomics and proteomics, and also be useful in drug discovery.</p><p>In a proof-of-principle study, his team conducted a comprehensive analysis of the ultrastructural morphological differences between cancer cells cultured as 3D tumorspheres and those cultured as 2D monolayers. The samples were frozen, fixed and then prepared to be imaged with a scanning electron microscope. The tumorsphere model more accurately represented the in vivo tumor structure, they found, including a diverse array of mitochondrial morphologies exclusively in the 3D culture. (<em>Journal of Structural Biology</em>, 2023)</p><iframe src="https://cdn.embedly.com/widgets/media.html?src=https%3A%2F%2Fwww.youtube.com%2Fembed%2FG8MNMC3nxKI&amp;display_name=YouTube&amp;url=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3DG8MNMC3nxKI&amp;image=http%3A%2F%2Fi.ytimg.com%2Fvi%2FG8MNMC3nxKI%2Fhqdefault.jpg&amp;type=text%2Fhtml&amp;schema=youtube" width="854" height="480" frameborder="0" scrolling="no"><a href="https://medium.com/media/a64927053af53084251abf242d75a26b/href">https://medium.com/media/a64927053af53084251abf242d75a26b/href</a></iframe><p>Bostina compares vEM’s development stage to cryoEM before the resolution revolution. Frozen samples are sliced and imaged by a scanning or transmission electron microscope. They don’t have to be labeled. Then software must be trained on features of interest, such as mitochondria or chromosomes. vEM now involves a piecemeal workflow, with multiple formats that require user skills to get the data from one part to another.</p><p>The Bostina lab has made its software available on SBGrid (Volume Segmentation Tool (VST). He cautions that software trained on one sample doesn’t automatically work on another. “Brain cells are very different from stomach cells and very different from skin cells,” he says, adding that AI methods are not very powerful yet for vEM.</p><p>“There’s a lot of space for people to develop tools,” he says, a lot of interest in making the software faster, better and more specific to certain cells.”</p><p><em>By Carol Cruzon Morton (</em><a href="https://medium.com/u/f67c2460605d"><em>carolmorton</em></a><em>)</em></p><p><em>Carol Cruzan Morton is a senior science writer and medical editor in Oregon. She contributes profiles to SBGrid and has also written for Science, Medscape, Oregonian, Boston Globe, and San Francisco Chronicle, among other publications.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=ec22f0f763e2" width="1" height="1" alt=""><hr><p><a href="https://medium.com/sbgrid-community-news/viruses-for-good-ec22f0f763e2">Viruses for Good</a> was originally published in <a href="https://medium.com/sbgrid-community-news">SBGrid Community News</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Open the Floodgates: How NC1 Makes TRPM4 Destroy Cancer Cells]]></title>
            <link>https://medium.com/sbgrid-community-news/open-the-floodgates-how-nc1-makes-trpm4-destroy-cancer-cells-fc20d3b2a003?source=rss----4f09a70358f6---4</link>
            <guid isPermaLink="false">https://medium.com/p/fc20d3b2a003</guid>
            <category><![CDATA[structural-biology]]></category>
            <category><![CDATA[sodium]]></category>
            <category><![CDATA[sbgrid]]></category>
            <category><![CDATA[necrosis]]></category>
            <category><![CDATA[cancer]]></category>
            <dc:creator><![CDATA[SBGrid]]></dc:creator>
            <pubDate>Fri, 31 Jul 2026 02:27:30 GMT</pubDate>
            <atom:updated>2026-07-31T02:28:14.939Z</atom:updated>
            <content:encoded><![CDATA[<h4>Publication Highlight</h4><p><em>This publication highlight is part of the SBGrid Communities Project focused on science education and demonstrating how structural biology and preclinical science connect to medicine, a collaboration between SBGrid PI Piotr Sliz and Jamaine Davis of Belmont University.</em></p><p>Like a selective floodgate, TRPM4 allows sodium and water to rush into the cell, driving the progression of many cancers. Because of this important role researchers have targeted it for therapeutic intervention, hoping to block TRPM4 with small molecules, but have had little success due to its molecular binding incompatibility. Instead of focusing on blocking the channel, scientists pivoted to forcibly opening TRPM4 with the small molecule Necrocide 1 (NC1), which has been shown to destroy breast cancer cells. NC1 has also been found to destroy many other cancer cell types through a process called Necrosis by Sodium Overload (NECSO). This form of cell death, caused by sodium and water overload in the cell, overrides the cancer cell’s typical evasion mechanisms. However, this form of cell death does not occur in mouse models. SBGrid member Youxing Jiang from UT Southwestern Medical Center and colleagues identified key residues and binding sites that affect NC1’s ability to bind and activate TRPM4, thereby advancing our understanding of NC1 as an anticancer drug.</p><p>To confirm how NC1 binds to TRPM4, electrophysiological, structural, and functional analyses were performed. Researchers confirmed that NC1 activates TRPM4 by binding near the Ca2+ activation site, but only in the presence of the lipid PI(4,5)P₂, and that hydrophobic and polar interactions stabilize it. The mechanisms following binding mirror those observed in TRPM4 upon Ca2+ binding and include the adoption of an intermediate closed TRPM4 conformation and a shift in the S3 and S4 helices, resulting in sustained channel activation. To elucidate which residues are capable of hindering activation, a series of tryptophan mutations were carried out, and three (Y790, L824, and I909) were found to block NC1 from binding and therefore prevent activation.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*etkv_-C6wyXRYS6PV5konw.png" /><figcaption>Superimposed view of the human TRPM4 channel bound to NC1, Ca2+, and PI(4,5)P2​. Human TRPM4 (gray) is shown in an open state bound to Necrocide 1 (NC1; A1CY8), calcium (Ca2+; CA), and PI(4,5)P2​ (PT5). Highlighted key residues include Y790 (orange), L824 (light blue), and I909 (teal) for NC1 binding/activation, and R1064 (red) for human specificity. CC by SBGrid.</figcaption></figure><p>Jiang and colleagues next turned their attention to understanding binding specificity. Before using comparative studies to activate TRPM4 with NC1 across different cell lines, mice, and hamsters, the initial results suggested that NC1 insensitivity in non-human mammals was due to low TRPM4 expression. Further structural studies refuted these results. Researchers identified R1064 as the key residue in NC1 specificity. The suspected residues, in combination with R1064, were mutated in mouse counterparts, resulting in significant increases in NC1 sensitivity. Additionally, while humans naturally possess an arginine at position 1064 (R1064), other mammals natively express a serine at this equivalent site. This variation disrupts the binding pocket, further confirming the critical role of R1064 in NC1 binding specificity.</p><p>Altogether, researchers uncovered key aspects of NC1 binding and specificity. This study also opens several promising directions for future research. It shows that even a single amino acid substitution can alter a small molecule’s ability to bind and activate TRPM4. Because NC1 sensitivity is limited in non-human models, preclinical trials in human models are needed to obtain accurate results. Although many screenings and in vivo experiments remain to be performed, the results reported in this paper have laid the groundwork for future use of NC1 in TRPM4-targeted therapies.</p><p>Read more in <a href="https://doi.org/10.1038/s41467-026-74814-2"><strong><em>Nature Communications</em></strong></a>.</p><p><em>By Cariuna M. Ellison (</em><a href="https://medium.com/u/b8a86fe2142b"><em>Cariuna Ellison</em></a><em>), Fisk University</em></p><p><em>Cariuna M. Ellison is an undergraduate student at Fisk University, pursuing a Bachelor’s degree in Biochemistry and Molecular Biology. She is on track to graduate in May 2028. In her free time, she enjoys reading, exercising, and giving back to her community in any way she can.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=fc20d3b2a003" width="1" height="1" alt=""><hr><p><a href="https://medium.com/sbgrid-community-news/open-the-floodgates-how-nc1-makes-trpm4-destroy-cancer-cells-fc20d3b2a003">Open the Floodgates: How NC1 Makes TRPM4 Destroy Cancer Cells</a> was originally published in <a href="https://medium.com/sbgrid-community-news">SBGrid Community News</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>